Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 10/20 | 0.58 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3930648 | 0.78 | NAAA (0.58) | NAAACTSLALDH1A1GAATSHR | |
| SCHEMBL765661 | 0.78 | NAAA (0.58) | NAAACTSLALDH1A1GAATSHR | |
| SCHEMBL5180974 | 0.78 | NAAA (0.58) | NAAACTSLALDH1A1GAATSHR | |
| SCHEMBL5200673 | 0.76 | CRBN (0.60) | NAAACTSLALDH1A1GAATSHR | |
| SCHEMBL3544056 | 0.76 | CRBN (0.60) | NAAACTSLALDH1A1GAATSHR | |
| SCHEMBL632914 | 0.76 | CRBN (0.60) | NAAACTSLALDH1A1GAATSHR | |
| SCHEMBL4079431 | 0.75 | NAAA (0.85) | NAAACTSL | |
| SCHEMBL4073930 | 0.75 | NAAA (0.85) | NAAACTSL | |
| SCHEMBL4073924 | 0.75 | NAAA (0.85) | NAAACTSL | |
| SCHEMBL5105468 | 0.74 | NAAA (0.52) | NAAACTSLEPHX1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137803-A1 | 5-PROTECTED AMINOPYRIMIDINE COMPOUND, PRODUCTION METHOD THEREOF AND INTERMEDIATE THEREFOR | AJINOMOTO CO., INC. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7507738-B2 | 5-protected aminopyrimidine compound, production method thereof and intermediate therefor | AJINOMOTO CO., INC. (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20050209257-A1 | 5-Protected aminopyrimidine compound, production method thereof and intermediate therefor | AJINOMOTO CO., INC. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1577303-A1 | 5-protected aminopyrimidine compound, production method thereof and intermediate thereof | Ajinomoto Co., Inc. (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209257-A1 | 5-Protected aminopyrimidine compound, production method thereof and intermediate therefor | DPYD, DHPS, DHFR | NAAA 1071/4885CTSL 3214/4885EPHX1 1928/4885 |
| US-20090137803-A1 | 5-PROTECTED AMINOPYRIMIDINE COMPOUND, PRODUCTION METHOD THEREOF AND INTERMEDIATE THEREFOR | DPYD, DHPS, DHFR | NAAA 1071/4885CTSL 3214/4885EPHX1 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.